Ameriprise Financial Inc Replimune Group, Inc. Transaction History

Ameriprise Financial Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $92,960 - $175,530	18,555 New	18,555 $166,000
Q3 2023 Nov 14, 2023	SELL	$15.96 - $22.18 $13,534 - $18,808	-848 Reduced 0.45%	186,779 $3.2 Million
Q2 2023 Aug 14, 2023	SELL	$15.65 - $24.1 $310,683 - $478,433	-19,852 Reduced 9.57%	187,627 $4.36 Million
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $125,856 - $209,448	-7,200 Reduced 3.35%	207,479 $3.66 Million
Q4 2022 Feb 14, 2023	SELL	$17.09 - $27.91 $34,009 - $55,540	-1,990 Reduced 0.92%	214,679 $5.84 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $3.38 Million - $4.58 Million	216,669 New	216,669 $3.74 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.